NSAIDs and the gastrointestinal tract

Current Gastroenterology Reports

Volumn 11, Issue 5, 2009, Pages 345-353

  Gupta, Maneesh ^a   Eisen, Glenn M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CALGRANULIN A; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; FOLIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LANSOPRAZOLE; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB;

ABDOMINAL CRAMP; ADENOMATOUS POLYP; ARTHRITIS; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COLITIS; COLON DIVERTICULOSIS; COLON HEMORRHAGE; COLON PERFORATION; COLON STENOSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE MARKER; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; ENTEROPATHY; GASTRIC ULCER BLEEDING; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HELICOBACTER INFECTION; HIGH RISK PATIENT; HUMAN; INTESTINE ULCER; LOW DRUG DOSE; PEPTIC ULCER; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STOMACH EROSION; STOMACH MUCOSA INJURY; STOMACH ULCER; STROKE; TREATMENT DURATION; ULCER;

ADENOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; DUODENAL ULCER; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; PROTON PUMP INHIBITORS; RISK ASSESSMENT; STOMACH ULCER;

EID: 70349489885     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0053-z     Document Type: Review

References (75)

1. Abraham NS, Castillo DL, Hartman C: National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther 2008, 28:97-106.
2. Bidaut-Russell M, Gabriel SE: Adverse gastrointestinal effects of NSAIDs: Consequences and costs. Best Pract Res Clin Gastroenterol 2001, 15:739-753.
3. Pounder R: Silent peDtic ulceration: deadly silence or golden silence? Gastroenterology 1989, 96:626-631.
4. Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594-606.
5. Singh G, Triadafilopoulos G: Epidemiology of NSAIDinduced gastrointestinal complications. J Rheumatol Suppl 1999, 56:18-24.
6. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
7. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
8. Silverstein FE, Graham DY, Senior JR, et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249.
9. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796.
10. Griffin MR, Piper JM, Daugherty JR, et al.: Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991, 114:257-263.
11. Piper JM, Ray WA, Daugherty JR, Griffin MR: Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991, 114:735-740.
12. Shorr RI, Ray WA, Daugherty JR, Griffin MR: Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993, 153:1665-1670.
13. Lanza FL, Chan FK, Quigley EM: Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
14. Richy F, Bruyere O, Ethgen O, et al.: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: A consensus statement using a meta-analytic approach. Ann Rheum Dis 2004, 63:759-766.
15. McQuaid KR, Laine L: Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006, 119:624-638.
16. Sorensen HT, Mellemkjaer L, Blot WJ, et al.: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000, 95:2218-2224.
17. Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002, 359:14-22.
18. Vergara MR Catalan M, Gisbert JP, Calvet X: Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005, 21:1411-1418.
19. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ: Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: A systematic review. Clin Gastroenterol Hepatol 2006, 4:130-142.
20. Chan FK, To KF, Wu JC, et al.: Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting longterm treatment with non-steroidal anti-inflammatory drugs: A randomised trial. Lancet 2002, 359:9-13.
21. Leontiadis GI, Sreedharan A, Dorward S, et al.: Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007, 11:iIi-iv, 1-164.
22. El-Serag HB, Graham DY, Richardson P, Inadomi JM: Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: The use of a nomogram in cost-effectiveness analysis. Arch Intern Med 2002, 162:2105-2110.
23. Chan FK, Chung SC, Suen BY, et al.: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
24. Arents NL, Thijs JC, van Zwet AA, et al.: Approach to treatment of dyspepsia in primary care: A randomized trial comparing "test-and-treat" with prompt endoscopy. Arch Intern Med 2003, 163:1606-1612.
25. Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB: Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomised trial. Lancet 2000, 356:455-460.
26. Manes G, Menchise A, de Nucci C, Balzano A: Empirical prescribing for dyspepsia: Randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003, 326:1118.
27. Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727-734.
28. Simon LS, Hatoum HT, Bittman RM, et al.: Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial. Family Medicine 1996, 28:204-210.
29. Graham DY, Agrawal NM, Campbell DR, et al.: Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002, 162:169-175.
30. Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999, 354: 2106-2111.
31. Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999, 282: 1921-1928.
32. Schnitzer TJ, Burmester GR, Mysler E, et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364: 665-674.
33. Laine L, Curtis SP, Cryer B, et al.: Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: A randomised comparison. Lancet 2007, 369:465-473.
34. Rostom A, Muir K, Dube C, et al.: Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007, 5: 818-828, 828.e1-5; quiz 768.
35. Chan FK, Hung LC, Suen BY, et al.: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 347:2104-2110.
36. Chan FK, Wong VW, Suen BY, et al.: Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial. Lancet 2007, 369:1621-1626.
37. Yeomans ND, Tulassay Z, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338:719-726.
38. Masso Gonzalez EL, Garcia Rodriguez LA: Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: An observational study. Aliment Pharmacol Ther 2008, 28:629-637.
39. Ehsanullah RS, Page MC, Tildesley G, Wood JR: Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988, 297:1017-1021.
40. Robinson MG, Griffin JW Jr, Bowers J, et al.: Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989, 34:424-428.
41. Taha AS, Hudson N, Hawkey CJ, et al.: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996, 334:1435-1439.
42. Cannon CP, Curtis SP, FitzGerald GA, et al.: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet 2006, 368:1771-1781.
43. Rahme E, Barkun A, Nedjar H, et al.: Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008, 103:872-882.
44. Bjarnason I, Zanelli G, Smith T, et al.: Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987, 93:480-489.
45. Bjarnason I, Takeuchi K: Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009, 44(Suppl 19):23-29.
46. Matsumoto T, Kudo T, Esaki M, et al.: Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: A Japanese multicenter study. Scand J Gastroenterol 2008, 43:490-496.
47. Graham DY, Opekun AR, Willingham FF, Qureshi WA: Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005, 3:55-59.
48. Goldstein JL, Eisen GM, Lewis B, et al.: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005, 3:133-141.
49. Tibble JA, Sigthorsson G, Foster R, et al.: High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999, 45:362-366.
50. Maiden L, Thjodleifsson B, Theodors A, et al.: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128:1172-1178.
51. Goldstein JL, Eisen GM, Lewis B, et al.: Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007, 25:1211-1222.
52. Smecuol E, Pinto Sanchez MI, Suarez A, et al.: Low-dose aspirin affects the small bowel mucosa: Results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009, 7:524-529.
53. Montalto M, Curigliano V, Santoro L, et al.: Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. Eur J Gastroenterol Hepatol 2006, 18:965-967.
54. Lengeling RW, Mitros FA, Brennan JA, Schulze KS: Ulcerative ileitis encountered at ileo-colonoscopy: Likely role of nonsteroidal agents. Clin Gastroenterol Hepatol 2003, 1:160-169.
55. Morris AJ, Wasson LA, MacKenzie JF: Small bowel enteroscopy in undiagnosed gastrointestinal blood loss. Gut 1992, 33:887-889.
56. Kessler WF, Shires GT 3rd, Fahey TJ 3rd: Surgical complications of nonsteroidal antiinflammatory drug-induced small bowel ulceration. J Am Coll Surg 1997, 185:250-254.
57. Smale S, Tibble J, Sigthorsson G, Bjarnason I: Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Pract Res Clin Gastroenterol 2001, 15:723-738.
58. Evans JM, McMahon AD, Murray FE, et al.: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619-622.
59. Felder JB, Korelitz BI, Rajapakse R, et al.: Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study. Am J Gastroenterol 2000, 95:1949-1954.
60. Biancone L, Tosti C, Geremia A, et al.: Rofecoxib and early relapse of inflammatory bowel disease: An open-label trial. Aliment Pharmacol Ther 2004, 19:755-764.
61. Matuk R, Crawford J, Abreu MT, et al.: The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:352-356.
62. Sandborn WJ, Stenson WF, Brynskov J, et al.: Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006, 4:203-211.
63. Takeuchi K, Smale S, Premchand P, et al.: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:196-202.
64. Laine L, Connors LG, Reicin A, et al.: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003, 124:288-292.
65. Laine L, Curtis SP, Langman M, et al.: Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008, 135:1517-1525.
66. Baron JA, Cole BF, Sandler RS, et al.: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348:891-899.
67. Sandler RS, Halabi S, Baron JA, et al.: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348:883-890.
68. Steinbach G, Lynch PM, Phillips RKS, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952.
69. Benamouzig R, Deyra J, Martin A, et al.: Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 2003, 125:328-336.
70. Dube C, Rostom A, Lewin G, et al.: The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007, 146:365-375.
71. Logan RF, Grainge MJ, Shepherd VC, et al.: Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008, 134:29-38.
72. Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873-884.
73. Baron JA, Sandler RS, Bresalier RS, et al.: A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131:1674-1682.
74. Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885-895.
75. Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2009, 2:310-321.